The latest gastro-intestinal cancer news
Appendix cancer rising among younger generation
Justin Stebbing, Anglia Ruskin University Appendix cancer is a condition that, until recently, was so…
Browsing: GI Cancers
ASCO 2025: First phase 2 RCT of CAR T-cell therapy in solid tumours finds promising results
Patients with advanced gastric or gastro-oesophageal junction (GEJ) cancer treated with CAR T-cell therapy lived…
ASCO 2025: Trastuzumab deruxtecan can help some people with advanced gastric cancers live about 3 months longer
The international phase 3 DESTINY-Gastric04 clinical trial found that second-line treatment with trastuzumab deruxtecan can help…
ASCO 2025: Exercise programme may lower risk of recurrence and death for some colon cancer survivors
New study results show that a structured exercise programme following surgery and adjuvant chemotherapy reduced…
ASCO 2025: Perioperative treatment with durvalumab and FLOT chemo can reduce risk of recurrence for some gastric cancers
Results from an international phase 3 clinical trial found that treating stage II, III, and…
ASCO 2025: Zanidatamab plus chemotherapy shows strong first-line efficacy in HER2-positive gastro-oesophageal adenocarcinoma
A phase 2 trial reports high response rates and durable outcomes in treatment-naive patients, presented…
Can gut microbes save patients from chemotherapy side effects?
Chemotherapy doesn’t just kill cancer cells. It also affects the microbes in the digestive tract. Researchers…
Immune side effects of liver cancer therapy studied in Latin American patients
A new research paper was published in Volume 16 of Oncotarget on May 19, 2025, titled “Immune-mediated adverse…
Team creates light-activated therapy to target hard-to-treat cancer
University of Texas at Dallas bioengineers, in collaboration with UT Southwestern Medical Centre researchers, are…
Oleanolic acid restores drug sensitivity in sorafenib-resistant hepatocellular carcinoma
Hepatocellular carcinoma (HCC) remains challenging to treat in advanced stages, primarily due to the development…